Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.
Humans
Carbidopa
/ administration & dosage
Levodopa
/ administration & dosage
Immunotherapy, Adoptive
/ adverse effects
Parkinsonian Disorders
/ drug therapy
Drug Combinations
Treatment Outcome
Amantadine
/ administration & dosage
Male
Middle Aged
Dopamine Agents
/ administration & dosage
Female
Drug Therapy, Combination
Indoles
/ administration & dosage
Dopamine Agonists
/ administration & dosage
Antiparkinson Agents
/ administration & dosage
Biological Products
/ administration & dosage
Receptors, Chimeric Antigen
/ immunology
CAR-T
ciltacabtagene autoleucel
movement and neurocognitive toxicity
multiple myeloma
parkinsonism
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
06
2024
accepted:
29
08
2024
medline:
7
10
2024
pubmed:
7
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.
Identifiants
pubmed: 39372422
doi: 10.3389/fimmu.2024.1444010
pmc: PMC11449727
doi:
Substances chimiques
Carbidopa
MNX7R8C5VO
Levodopa
46627O600J
carbidopa, levodopa drug combination
0
Drug Combinations
0
ropinirole
030PYR8953
Amantadine
BF4C9Z1J53
axicabtagene ciloleucel
U2I8T43Y7R
Dopamine Agents
0
Indoles
0
Dopamine Agonists
0
Antiparkinson Agents
0
Biological Products
0
Receptors, Chimeric Antigen
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1444010Informations de copyright
Copyright © 2024 Aliakbar, Manouvakhova, Wong, Htut, Pulst-Korenberg, Janakiram, Rosenzweig, Goldsmith and Mason.
Déclaration de conflit d'intérêts
MJ: consultancy: Jansen, Bristol-Myers Squibb; research funding: Bristol-Myers Squibb. SG: consultancy: Bristol-Myers Squibb, Janssen, Sanofi; research funding: Bristol-Myers Squibb, Ipsen; speaker bureau: Adaptive Biotechnologies, Janssen. XM: consultancy: Abbott Labs, Boston Scientific, and Janssen. Speaker bureau: Abbott Labs The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.